Mesenchymal Stem Cell Therapy for Performance and Recovery: What the Science Actually Says

‍By Dr. Cameron Chesnut | Five Codes Podcast — featuring Dr. Christopher Meadows MD, Double Board-Certified in Physical Medicine & Rehabilitation and Regenerative Medicine

There's a version of this conversation that happens in waiting rooms and wellness forums every day: someone has done everything right — they're exercising, eating well, sleeping, managing stress — and yet their body isn't keeping pace with how they feel on the inside. Not in the mirror, not on the trail, not on the court.

For Dr. Cameron Chesnut, that gap is the core problem his surgical practice is built around. For Dr. Christopher Meadows, it's the same gap, just expressed physically rather than aesthetically. The patient coming to Dr. Meadows isn't saying "I don't look how I feel." They're saying "I don't move how I feel." Something is limiting them, and they can't close the gap through training alone.

In this episode of the Five Codes Podcast, the two discuss where their practices intersect: in the biology of cellular optimization, recovery, and the science of mesenchymal stem cell (MSC) therapy. What follows is a deeper read for those who want the evidence behind the conversation.

What Is a Stem Cell, Really?

A stem cell is defined by two properties: the ability to self-replicate, and the capacity to differentiate, meaning it can develop into other specialized tissue types, including bone, cartilage, fat, and nerve tissue.

That definition sounds simple, but it spans an enormous range of cell types, from embryonic stem cells capable of generating an entire organism, all the way to highly targeted adult stem cells designed to regenerate specific tissues.

The key insight from Dr. Meadows: earlier in the developmental lineage doesn't mean better for clinical use. A truly embryonic stem cell, capable of becoming any tissue, is actually too broad — it can produce heterogeneous, unpredictable tissue growth. The more clinically useful cells are those further along the lineage: still pluripotent enough to signal and regenerate, but naturally directed toward specific tissue targets. This is counterintuitive to most patients, who assume "more primitive equals more powerful."

For a deeper read: Caplan AI. Mesenchymal Stem Cells. Journal of Orthopaedic Research, 1991. The foundational paper coining the term "mesenchymal stem cells" and describing their multi-tissue differentiation potential. (PubMed)

The Three Sources of MSCs: and How to Choose

Mesenchymal stem cells (MSCs), now increasingly referred to as medicinal signaling cells, (a renaming that points to how they actually work), are clinically sourced from three primary locations:

Bone marrow has been the most studied source historically. The harvest procedure is more invasive, and because bone marrow is highly metabolically active, its stem cells have undergone more replication cycles, which affects quality markers like telomere length.

Adipose (fat) tissue is increasingly favored because fat is metabolically quiet, it's designed for storage. That means adipose-derived MSCs tend to have longer telomeres and display cellular characteristics associated with being "younger" at the functional level. They are also more accessible, harvested via a mini-liposuction procedure. Both of these sources are autologous — meaning they come from you and go back into you.

Umbilical cord tissue (specifically Wharton's Jelly) provides what are arguably the youngest available MSCs. These are sourced from full-term, consented donors from tissue that would otherwise be discarded. Because they come from a newborn, they show no hallmarks of cellular aging. They have the longest telomeres andhighest functional capacity by cellular metrics. These are allogeneic, meaning they can be used across donors without significant rejection risk.

Bottom line from the research: all three sources demonstrate similar clinical efficacy outcomes.

The differences are most relevant when choosing based on patient preference, procedural tolerance, and specific conditions.

The quality of the cells and the environment they're placed in matters more than the source.

For a deeper read: Pittenger MF et al. Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science, 1999. (PubMed)

For a deeper read on adipose-derived MSCs: Gimble JM et al. Adipose-Derived Adult Stem Cells: Isolation, Characterization, and Differentiation Potential. Cytotherapy, 2003. (PubMed)

How MSCs Actually Work: Signaling, Not Just Replacing

One of the most important (and most misunderstood) aspects of stem cell therapy is the mechanism of action.

The popular mental model: you inject a stem cell, it travels to the damaged tissue, embeds, and becomes new cartilage (or tendon, or fat). Clean and simple.

The reality is more nuanced, and arguably more interesting. The emerging consensus is that MSCs work primarily as signaling agents. That is, they release growth factors, cytokines, and other molecular signals that recruit the body's own healing cascade, reactivate stalled repair processes, and modulate local inflammation. Whether the administered stem cells themselves become new tissue, or whether they are cleared by the immune system after delivering their signals, is still an open question in the research literature.

As Dr. Meadows explains it: a stem cell injected into a damaged knee may not necessarily become new cartilage, but if cartilage regrowth is observed on post-treatment MRI and the patient is running again, does the mechanism matter as much as the outcome?

What's clear is that this signaling model actually reduces the safety concerns that made early embryonic stem cell work troubling. If the cells are primarily signaling and then being cleared, the risk of unwanted tissue transformation drops significantly. The 5-, 10-, and 15-year literature is bearing this out: the complications associated with early-generation approaches are not being seen with MSC-based therapies.

For a deeper read: Caplan AI & Correa D. The MSC: An Injury Drugstore. Cell Stem Cell, 2011. This is the paper that pivoted the field toward thinking of MSCs as medicinal signaling cells. (PubMed)

For a deeper read on MSC secretome: Meirelles LS et al. Mechanisms Involved in the Therapeutic Properties of Mesenchymal Stem Cells. Cytokine & Growth Factor Reviews, 2009. (PubMed))

Why Cell Passage Number Matters: The Question Most Clinics Won't Answer

This is one of the most practically important parts of the conversation, and one of the least discussed in patient-facing information.

Every time a stem cell is replicated in a lab, it goes through what's called a "passage." Passage 1 (P1) means it has been cultured and divided once. The higher the passage number, the more times the cell has replicated — and the more it has aged.

Research consistently shows that after passage 10, MSC function begins to meaningfully decline: fewer exosomes and growth factors are released, and the capacity for tissue differentiation decreases. For a cell to actually do what you need it to do clinically, you want it functioning at its peak: ideally at P5 or below.

This is why the "more cells = better" argument that drives a lot of medical tourism marketing is so misleading. Clinics offering 100 billion cells from a cell line that has been in culture for years (potentially at P100, P200, or higher) may be delivering cells that are essentially exhausted. Cell count is not the same as cell quality or cell function.

At practices operating under rigorous protocols, passage number is tracked and controlled. The question every patient should ask any provider: what is the passage number of the cells being administered?

For a deeper read: Bonab MM et al. Aging of mesenchymal stem cell in vitro. BMC Cell Biology, 2006. Documents the functional decline of MSCs across increasing passage numbers. (PubMed))

The Environment Matters as Much as the Cell

One of the most underappreciated variables in stem cell therapy is the environment the cells are placed into. A high-quality stem cell in a toxic or highly inflammatory environment will underperform — or fail to perform at all.

This is where metabolic health becomes directly relevant. Blood glucose control, systemic inflammation levels, cytotoxin burden, body composition: all of these affect the microenvironment that stem cells operate in. A patient who has optimized their metabolic health isn't just healthier in a general sense; they're providing their stem cells with a more favorable substrate to work in.

This also explains why pre-procedural optimization matters. In the six weeks before a procedure, meaningful changes can be made to the environment the stem cells will enter: reducing inflammation through diet and anti-inflammatory protocols, mobilizing circulating stem cells through fasting, hyperbaric oxygen therapy, and red light therapy, and cleaning up lifestyle variables that contribute to systemic burden.

These aren't optional enhancements. They are part of the mechanism.

For a deeper read on hyperbaric oxygen and stem cell mobilization: Thom SR et al. Stem cell mobilization by hyperbaric oxygen. American Journal of Physiology: Heart and Circulatory Physiology, 2006. (PubMed))

Stem Cell Banking: Why Earlier Is Better, But Later Still Works

Dr. Meadows and Dr. Chesnut both bank stem cells for their patients, and the logic is straightforward: if you can preserve a sample of your stem cells at their current quality, you have access to that quality in perpetuity, regardless of how your cellular age changes in the years ahead.

The nuance is that while banking earlier is preferable (younger cells have better telomere metrics and lower passage history from the outset), the literature shows meaningful clinical benefit from autologous stem cell use even in patients north of 70, provided their underlying metabolic health is solid. Age of the patient is a less reliable predictor of stem cell quality than overall metabolic status.

The practical implication: banking is valuable at any age, and it should not be deferred because someone feels they've "missed the window." There is no closed window, but opening it earlier does give you more to work with.

For a deeper read: Choudhery MS et al. Donor age negatively influences adipose tissue-derived mesenchymal stem cell expansion and differentiation. Journal of Translational Medicine, 2014. (PubMed))

MSC Therapy in Orthopedics: What the Evidence Shows

For the patient asking whether stem cells can actually help a damaged knee, shoulder, or spine, the honest answer from the current literature is: likely yes, with important caveats.

A 2023 review published in Cellular & Molecular Immunology evaluated 26 randomized and non-randomized clinical trials of MSC therapy in knee osteoarthritis. Across the studies, MSC treatment showed positive effects on pain reduction and function in the majority of trials, with cartilage protection or repair observed in 18 of 21 clinical studies reviewed.

The key variables that affect outcomes include: cell source and dose, the degree of existing tissue damage, and (as emphasized throughout this post) patient metabolic health and the quality of the cellular environment at the time of treatment.

MSC therapy is not a substitute for addressing the biomechanical root cause of an injury. Dr. Meadows' approach (watching patients move, assessing the kinetic chain, identifying where force is being redirected before injecting anything) reflects what the evidence also suggests: regenerative therapy works best when integrated into a comprehensive plan that addresses the underlying mechanics, not just the site of pain.

For a deeper read: Joswig AJ et al. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells. Stem Cell Research & Therapy, 2017. (PubMed))

For the clinical trial review: Lopa S et al. Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? Cellular & Molecular Immunology, 2023. (Nature))

On Medical Tourism and Overseas Stem Cell Clinics

This question comes up often, and it deserves a direct answer.

The issue with overseas stem cell treatment is not primarily legal, it's regulatory.

In the United States, the processes by which stem cells are harvested, handled, cultured, and administered are overseen by regulatory bodies designed to ensure donor quality, sterility, and cell integrity. Those same frameworks often don't exist in the destinations most commonly associated with stem cell medical tourism.

The result is that patients cannot reliably know the passage number, the source verification, or the actual cell count of what they're receiving. The marketing claims of dramatically high cell numbers (tens of billions) are often a signal of the opposite problem: highly replicated, functionally depleted cells.

There's also the follow-up problem. As Dr. Meadows notes: if you don't have a follow-up relationship, you don't have outcomes data, and neither does the clinic. The outcome measurement is what closes the loop between treatment and learning. Without it, you're receiving a procedure with no feedback mechanism and no accountability.

Frequently Asked Questions

What is a mesenchymal stem cell (MSC)?

A mesenchymal stem cell is a type of adult stem cell found primarily in bone marrow, fat tissue, and umbilical cord tissue. MSCs can self-replicate and differentiate into several tissue types including bone, cartilage, fat, and muscle. They are also increasingly understood to function as medicinal signaling cells: releasing growth factors and anti-inflammatory molecules that recruit the body's own healing mechanisms rather than directly replacing damaged tissue themselves.

Is stem cell therapy legal in the United States?

This question is often framed incorrectly. Stem cell therapies are not broadly "illegal" in the U.S., but they are regulated. Autologous treatments (using a patient's own cells, minimally manipulated) operate under a different regulatory framework than cultured or allogeneic products. The FDA oversees the handling, manipulation, and use of cell-based therapies to ensure safety. Most MSC therapies available from reputable U.S. practitioners fall within established regulatory pathways. The concern with overseas clinics is not that they're doing something "more" but it's that the regulatory oversight ensuring cell quality and patient safety is largely absent.

Do stem cells actually become new tissue, or do they just signal?

Both appear to happen, but signaling is likely the dominant mechanism in most clinical applications. When MSCs are introduced into an area of injury or degeneration, they release a cascade of growth factors and cytokines that reduce inflammation and stimulate the body's own repair processes. Whether those specific injected cells ultimately embed and become new cartilage or tendon tissue (or are cleared by the immune system after doing their signaling work) is still being studied. What's clear is that structural improvements (cartilage regrowth on MRI, tendon integrity) and functional improvements (return to activity, pain reduction) are observed in the clinical literature, regardless of which mechanism is dominant.

Does the number of stem cells injected matter? Is more better?

Not necessarily, and this is one of the most important things to understand about evaluating stem cell providers. Cell count is only meaningful in the context of cell quality. A high number of highly replicated (high passage number) cells may actually deliver less therapeutic benefit than a lower number of fresh, low-passage cells. There is a Goldilocks principle at work: there is likely an optimal dose range for a given condition, beyond which additional cells with poor functional capacity add little value. This is why "we use 100 billion cells" is a marketing claim, not a clinical one.

How does metabolic health affect stem cell therapy outcomes?

Significantly. Stem cells operate within the environment of the body they're introduced into. Elevated blood glucose, systemic inflammation, high cytotoxin burden, and poor metabolic health all create an unfavorable microenvironment that impairs stem cell function, regardless of the quality of the cells themselves. Optimizing metabolic health before a procedure (reducing inflammation, improving blood glucose regulation, using modalities like hyperbaric oxygen and fasting to mobilize circulating stem cells) is not optional preparation, it's part of the mechanism of the therapy.

What is stem cell banking, and should I do it?

Stem cell banking involves harvesting your own MSCs (typically from fat tissue via mini-liposuction) and cryopreserving them for future use. The rationale is that you preserve the cellular quality of your stem cells at their current age and health status, giving you access to those cells for future procedures indefinitely. Banking earlier is generally preferable because younger cells have better telomere metrics and functional capacity. However, research supports meaningful benefit from autologous stem cells even in older patients with good metabolic health, so banking at any age is preferable to not banking at all.

Can stem cell therapy help with recovery from surgery?

Yes, and this is one of the more compelling intersections of regenerative medicine and aesthetic or reconstructive surgery. MSCs introduced into a surgical site, either from fat transfer with high stem cell density or from banked cells, create a local signaling environment that appears to accelerate and improve healing. The effect is most notable in procedures where fat is transferred back to the treatment area: not only does the transferred tissue survive better, but the overall quality of the tissue in that region improves over time through ongoing paracrine (cell-to-cell signaling) activity. The clinical observation is faster recovery, better tissue integration, and improved long-term structural outcomes.

Listen to the Full Episode

This blog post is a companion to the Five Codes Podcast episode featuring Dr. Cameron Chesnut in conversation with Dr. Christopher Meadows.

🎧 Listen on Spotify🍎 Listen on Apple Podcasts▶️ Watch on YouTube

About the Guest & Host

Dr. Cameron Chesnut is a facial plastic surgeon and founder of Clinic 5C, where he leads a team focused on integrative cosmetic surgery, regenerative medicine, and functional health. He holds a clinical teaching affiliation with the University of Washington School of Medicine.

Dr. Christopher Meadows is double board-certified in Physical Medicine & Rehabilitation and Regenerative Medicine. His practice focuses on MSC-based therapies for orthopedic conditions, performance optimization, and whole-body cellular health.

The views shared here are the speakers' own and are not associated with or representative of any institutional affiliation. This content is for general educational purposes only and should not be considered individualized medical advice.

‍